NCT04965636 - Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

October 9, 2025

Study Completion Date

October 9, 2025

Conditions

Hypereosinophilic Syndrome

Interventions

DRUG

Mepolizumab

Mepolizumab will be provided in pre-filled safety syringe

Trial Locations (14)

GSK Investigational Site, Quilmes

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Ankara

GSK Investigational Site, Charleston

GSK Investigational Site, Izmir

GSK Investigational Site, Kayseri

GSK Investigational Site, Cleveland

GSK Investigational Site, Cincinnati

GSK Investigational Site, Petah Tikva

GSK Investigational Site, Rochester

GSK Investigational Site, Buenos Aires

GSK Investigational Site, São Paulo

GSK Investigational Site, Sorocaba

GSK Investigational Site, Rotterdam